ATRA Stockholders Have Rights - If You Lost Money Investing in Atara Biotherapeutics, Inc. Contact Robbins LLP for Information About Recovering Your Losses

Robbins LLP reminds stockholders that a class action was filed on behalf of all investors who purchased or otherwise acquired Atara Biotherapeutics, Inc. (NASDAQ: ATRA) securities between May 20, 2024 ...

ATRA Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in Atara Biotherapeutics, Inc. Securities Lawsuit -- The Gross Law Firm

The Gross Law Firm issues the following notice to shareholders of Atara Biotherapeutics, Inc. (NASDAQ: ATRA). Shareholders who purchased shares of ATRA during the class period listed are encouraged to ...
TMCnet

REMINDER: Atara Biotherapeutics, Inc. Investors With Significant Losses Must Act By May 22, 2026 - Contact Kirby McInerney LLP

Kirby McInerney LLP reminds Atara Biotherapeutics, Inc. ("Atara" or the "Company") (NASDAQ:ATRA) investors of the May 22, 2026 deadline to seek the role of lead plaintiff in a pending federal ...
The Motley Fool

Why Atara Biotherapeutics Stock Is Imploding Today

Shares of Atara Biotherapeutics (ATRA 3.73%), a leader in the off-the-shelf adoptive cell therapy space, lost as much as 22% of their value in early morning trading today. What event triggered this ...
Times Argus

Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel

Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients ...
FierceBiotech

After a series of clinical stumbles, Atara lays off 20% of staff and slims R&D focus

Just under a month after Atara Biotherapeutics’ multiple sclerosis cell therapy turned up inconclusive results in a mid-phase trial, the biotech is taking decisive action to reduce cash burn by laying ...
Yahoo Finance

Atara Biotherapeutics Announces Changes to Its Board of Directors

THOUSAND OAKS, Calif, September 03, 2025--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell ...
Business Wire

Atara Biotherapeutics Provides Update on Clinical Programs Related to EBVALLO™ (tabelecleucel) and ATA3219

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to ...
Yahoo Finance

Atara Biotherapeutics Announces Pricing of $16 Million Offering

THOUSAND OAKS, Calif., May 15, 2025--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell ...
Seeking Alpha

Atara Biotherapeutics Announces U.S. FDA Acceptance and Priority Review of the Biologics License Application for Tabelecleucel (Tab-cel®) for the Treatment of Epstein-Barr ...

THOUSAND OAKS, Calif.--(BUSINESS WIRE)-- Atara Biotherapeutics, Inc. (ATRA) (Nasdaq: ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform ...
Business Wire

Atara Biotherapeutics Names Cell Therapy & Oncology Leader Cokey Nguyen, Ph.D. as Chief Scientific Officer

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Atara Biotherapeutics, Inc. (Nasdaq: ATRA), a pioneer in T-cell immunotherapy, leveraging its novel allogeneic EBV T-cell platform to develop ...